Lead Principal Investigator definition

Lead Principal Investigator means any person named in the Letter of Award as a Lead Principal Investigator for the Research;
Sample 1Sample 2Sample 3
Lead Principal Investigator means, consistent with Section VI of this Agreement, the Principal Investigator designated by the other Principal Investigators pursuant to Section VI (B), who, as the lead organization, will submit the application for federal funds to the DOE under the FOA. The Lead Principal Investigator shall serve as the primary contact to the DOE.
Sample 1Sample 2
Lead Principal Investigator means the Inv as the overall lead in the conduct of the Research;
Sample 1

Examples of Lead Principal Investigator in a sentence

  • Multiple Investigator applications may be submitted as: (1) a single Lead Principal Investigator (PI) application with Co-PI(s) or (2) a Multiple PI application (with a single Contact PI).

  • For multiple applications associated with the same project, the Lead Principal Investigator should include a spreadsheet that displays the total budget for all partners.

  • Applicant/ Project ConsortiumA project consortium must be consisted of at least three eligible research teams from at least three different participating countries listed above.Each research team shall be led by a Principal Investigator (PI), and a consortium shall be led by a Lead Principal Investigator (Lead PI) specified among the PIs. The Lead PI will be responsible for running and managing the project.

  • Be careful using these hosting services as they too have security issues.

  • Where its chief executive officer is also the Lead Principal Investigator, the Host Institution shall appoint another person from the governing body to which the chief executive officer reports to represent the Host Institution.

  • The Lead Principal Investigator shall inform Grantor if scientific work on the Research is unable to commence within three (3) months from the beginning of the Term.

  • The Lead Principal Investigator (PI) or Project Director should not be changed unless unavoidable and only minor edits should be made, if necessary, to the title.

  • The Lead Principal Investigator, who is the EFRC Director, and anyone submitting on behalf of the Lead Principal Investigator must register for an account in PAMS prior to submitting a pre-application.

  • Proposals that exceed the institutional eligibility limit (beyond the first two submissions based on timestamp) will be returned without review regardless of the institution's role (lead, non-lead, subawardee) in the returned proposal..Limit on Number of Proposals per PI or Co-PI: 1An individual may serve as Lead Principal Investigator (PI) or Co-PI on only one proposal submitted to the IGE program per annual competition.

  • Each optional letter of collaboration may contain two and only two sentences and must use the following format: Dear <Lead Principal Investigator Name>: If your application / proposal entitled, “<Application Name>,” is selected for funding by DOE, it is my intent to collaborate in this research by <Complete sentence with a very short description of what the collaborator offers to do or provide>.


More Definitions of Lead Principal Investigator

Lead Principal Investigator or ‘Lead PI” means the person named in the Letter of Award as Lead Principal Investigator for the Research;
Sample 1

Related to Lead Principal Investigator

  • Principal Investigator or “PI” is the person, designated by University, and accepted by Sponsor, who is directly responsible for executing, directing, overseeing and reporting a Sponsored Project under this Agreement.

  • Private investigator means any individual who engages in the business of, or accepts employment

  • Investigator means an individual who is:

  • clinical investigation means any systematic investigation in one or more human subjects, undertaken to assess the safety or performance of a device;

  • Investigators means those persons authorised, appointed, consulted or approached by the Chairman of the Audit Committee and includes the Auditors of the Company and the Police.

  • Collaborating physician means the physician who,

  • CRO means a contract research organization.

  • Researcher means a person appointed by us to carry out research into theoperation of this Contract;

  • Clinical Trials means a controlled study in humans of the safety or efficacy of a Product, and includes, without limitation, such clinical trials as are designed to support expanded labeling or to satisfy the requirements of an Agency in connection with any Product Approval and any other human study used in research and Development of a Product.

  • Public research university means Rutgers, The State University

  • Clinical Trial means a Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial, or any post-approval human clinical trial, as applicable.

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, as applicable.

  • Pivotal Clinical Trial means a pivotal human clinical trial of a Licensed Product with a defined dose or a set of defined doses of such Licensed Product designed to ascertain efficacy and safety of such Licensed Product for the purpose of enabling the preparation and submission of an MAA to the competent Regulatory Authorities in a country of the Territory, as further defined in 21 C.F.R. § 312.21(c) for the U.S., as amended from time to time, or the corresponding foreign regulations.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • clinical evidence means clinical data and clinical evaluation results pertaining to a device of a sufficient amount and quality to allow a qualified assessment of whether the device is safe and achieves the intended clinical benefit(s), when used as intended by the manufacturer;

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Clinical Studies means Xxxxx 0, Xxxxx 0, Xxxxx 0, Xxxxx 3, and such other tests and studies in human subjects that are required by Applicable Law, or otherwise recommended by the Regulatory Authorities, to obtain or maintain Regulatory Approvals for a Licensed Product for one (1) or more indications, including tests or studies that are intended to expand the Product Labeling for such Licensed Product with respect to such indication.

  • JPC means Joint Planning Committee.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Research Analyst means any individual employed by Loomis Sayles who has been designated as a Research Analyst or Research Associate by Loomis Sayles. A person is considered a Research Analyst only as to those Covered Securities which he or she is assigned to cover and about which he or she issues research reports to other Investment Persons or otherwise makes recommendations to Investment Persons beyond publishing their research. As to other securities, he or she is simply an Access Person.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Principal instructor means the individual who has the primary responsibility for organizing and teaching a particular course.